中国药物应用与监测
中國藥物應用與鑑測
중국약물응용여감측
CHINESE JOURNAL OF DRUG APPLICATION AND MONITORING
2013年
5期
252-253,254
,共3页
小细胞肺癌%依托泊苷%顺铂%肝转移%肝功能异常
小細胞肺癌%依託泊苷%順鉑%肝轉移%肝功能異常
소세포폐암%의탁박감%순박%간전이%간공능이상
Small cell lung cancer%Etoposide%Cisplatin%Hepatic metastasis%Liver dysfunction
目的::探讨小剂量EP方案(依托泊苷+顺铂)治疗小细胞肺癌肝转移合并严重肝功能异常患者的肝功能改善情况。方法:收集2007-2012年我院肿瘤科收治的小细胞肺癌肝转移初治患者,且治疗前血清生化检查天门冬氨酸氨基转移酶(AST)≥正常值上限5倍及/或丙氨酸氨基转移酶(ALT)≥正常值上限5倍,总胆红素(TBIL)≥正常值上限3倍。应用依托泊苷100 mg静脉滴注,d1~5;顺铂20 mg,d1~5,21 d为1周期,进行化疗2周期后,再次检测患者的肝功能指标。结果:共有8名患者纳入本研究,经过化疗后,所有患者肝功能指标均下降。结论:在无其他肝脏疾病的前提下,小剂量EP方案对于小细胞肺癌肝转移合并肝功能严重异常的患者较为安全,对改善患者肝脏功能有一定效果,临床疗效有待进一步探索。
目的::探討小劑量EP方案(依託泊苷+順鉑)治療小細胞肺癌肝轉移閤併嚴重肝功能異常患者的肝功能改善情況。方法:收集2007-2012年我院腫瘤科收治的小細胞肺癌肝轉移初治患者,且治療前血清生化檢查天門鼕氨痠氨基轉移酶(AST)≥正常值上限5倍及/或丙氨痠氨基轉移酶(ALT)≥正常值上限5倍,總膽紅素(TBIL)≥正常值上限3倍。應用依託泊苷100 mg靜脈滴註,d1~5;順鉑20 mg,d1~5,21 d為1週期,進行化療2週期後,再次檢測患者的肝功能指標。結果:共有8名患者納入本研究,經過化療後,所有患者肝功能指標均下降。結論:在無其他肝髒疾病的前提下,小劑量EP方案對于小細胞肺癌肝轉移閤併肝功能嚴重異常的患者較為安全,對改善患者肝髒功能有一定效果,臨床療效有待進一步探索。
목적::탐토소제량EP방안(의탁박감+순박)치료소세포폐암간전이합병엄중간공능이상환자적간공능개선정황。방법:수집2007-2012년아원종류과수치적소세포폐암간전이초치환자,차치료전혈청생화검사천문동안산안기전이매(AST)≥정상치상한5배급/혹병안산안기전이매(ALT)≥정상치상한5배,총담홍소(TBIL)≥정상치상한3배。응용의탁박감100 mg정맥적주,d1~5;순박20 mg,d1~5,21 d위1주기,진행화료2주기후,재차검측환자적간공능지표。결과:공유8명환자납입본연구,경과화료후,소유환자간공능지표균하강。결론:재무기타간장질병적전제하,소제량EP방안대우소세포폐암간전이합병간공능엄중이상적환자교위안전,대개선환자간장공능유일정효과,림상료효유대진일보탐색。
Objective: To observe the improvement of liver function by using low-dose EP regimen (etoposide and cisplatin) in small cell lung cancer patients with hepatic metastasis and severe liver dysfunction. Methods:From 2007 to 2012, chemotherapy-naive patients who had small cell lung cancer with severe liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase≥5×ULN, total bilirubin≥3×ULN before chemotherapy) secondary to hepatic metastasis were recruited, and treated with low-dose EP regimen which was intravenous infusion of etoposide 100 mg and cisplatin 20 mg from day 1 to 5 with every 3 weeks as a cycle. Liver function indexes were tested after two cycles of chemotherapy. Results:All those patients' liver function improved after chemotherapy. Conclusion:After the exclusion of other liver diseases, low-dose EP regimen was relatively safe in the small cell lung cancer patients with hepatic metastasis and severe liver dysfunction, and could improve the patients' liver function. The further study should be warranted to conifrm the clinical effect.